MBody AI Sets Dec 22 AGM: 175M Share Authorization, 1.84M-Share Equity Plan, New External Directors
MBAI sits 31% above its 52-week low of $1.611 on light trading volume (0.3× avg).
Summary
MBody AI's first post-merger annual meeting asks shareholders to expand authorized shares from 18 million to 175 million, adopt a 1.84-million-share equity plan, elect two external directors required by its new controlling shareholder, and approve CEO and director pay.
Key Events · Corporate Governance and Compliance · MBAI
-
Authorized Shares to Rise to 175 Million
Proposal 2 would lift authorized capital from 18,000,000 to 175,000,000 Ordinary Shares, conditional on the no-par-value amendment in Proposal 1. That leaves roughly 157.7 million authorized-but-unissued shares after the meeting — a multi-year capacity for financings and acquisitions, and a standing dilution overhang rather than shares actually sold.
-
Equity Plan Reserves 12% of Shares
The 2026 Equity Incentive Plan reserves 1,841,517 Ordinary Shares, about 12% of the 15,345,971 shares outstanding as of November 13, 2026. The reserve is fixed with no evergreen feature; the prior 2015 plan expired June 23, 2025.
-
Two External Directors Required
Because Chairman Regan McGee holds approximately 45% and is a controlling shareholder, the Nasdaq exemption from Israeli external-director rules ended at the August 26, 2026 closing. Fiona George and Daniel Kokiw are nominated; if they fail, the board falls below its four-director minimum and Proposals 8 and 9 cannot be voted.
-
CEO Pay: $375,000 Base Plus 150% Bonus
John Fowler's terms set a US$375,000 base salary, bonus up to 150% of base, a US$112,500 sign-on bonus, 12 months' severance and a parent guarantee of the MBody AI Corp. employment agreement. No equity grant is proposed at this meeting.
Analysis · MBAI · Technology
This is the first shareholder meeting since the August 26, 2026 merger, and it bundles the governance housekeeping the deal left undone with a large expansion of the share authorization. The headline item is raising authorized capital from 18,000,000 to 175,000,000 shares — roughly 157.7 million shares of headroom against 15,345,971 outstanding, which gives the Board room for years of financings and acquisitions without another vote. That is a standing dilution overhang, not dilution that has occurred. Alongside it, the 2026 Equity Incentive Plan reserves 1,841,517 shares (about 12% of the current count), and the company must elect two external directors because Chairman Regan McGee's ~45% stake made it a controlled company and killed its Nasdaq exemption. The two-session structure exists because Israeli law requires the new external directors to sit on the compensation committee before shareholders can vote on pay. Failure of the external-director vote would leave the board below its four-director minimum and force a follow-up meeting.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBAI was trading at $2.12 on NASDAQ in the Technology sector, with a market capitalization of approximately $32.3M. The 52-week trading range was $1.61 to $27.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.